These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
338 related articles for article (PubMed ID: 25827526)
1. Histone H3 peptide based LSD1-selective inhibitors. Kakizawa T; Ota Y; Itoh Y; Tsumoto H; Suzuki T Bioorg Med Chem Lett; 2015 May; 25(9):1925-8. PubMed ID: 25827526 [TBL] [Abstract][Full Text] [Related]
2. Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors. Kakizawa T; Ota Y; Itoh Y; Suzuki T Bioorg Med Chem Lett; 2018 Jan; 28(2):167-169. PubMed ID: 29198865 [TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating α,α-Disubstituted Amino Acids with γ-Turn-Inducing Structures. Ota Y; Kakizawa T; Itoh Y; Suzuki T Molecules; 2018 May; 23(5):. PubMed ID: 29734782 [TBL] [Abstract][Full Text] [Related]
4. Development and crystallographic evaluation of histone H3 peptide with N-terminal serine substitution as a potent inhibitor of lysine-specific demethylase 1. Amano Y; Kikuchi M; Sato S; Yokoyama S; Umehara T; Umezawa N; Higuchi T Bioorg Med Chem; 2017 May; 25(9):2617-2624. PubMed ID: 28336409 [TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors. Culhane JC; Wang D; Yen PM; Cole PA J Am Chem Soc; 2010 Mar; 132(9):3164-76. PubMed ID: 20148560 [TBL] [Abstract][Full Text] [Related]
6. Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors. Nie Z; Shi L; Lai C; Severin C; Xu J; Del Rosario JR; Stansfield RK; Cho RW; Kanouni T; Veal JM; Stafford JA; Chen YK Bioorg Med Chem Lett; 2019 Jan; 29(1):103-106. PubMed ID: 30409536 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological activity of 3-oxoamino-benzenesulfonamides as selective and reversible LSD1 inhibitors. Xi J; Xu S; Wu L; Ma T; Liu R; Liu YC; Deng D; Gu Y; Zhou J; Lan F; Zha X Bioorg Chem; 2017 Jun; 72():182-189. PubMed ID: 28460360 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors. Ota Y; Miyamura S; Araki M; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Itami K; Yamaguchi J; Suzuki T Bioorg Med Chem; 2018 Feb; 26(3):775-785. PubMed ID: 29331452 [TBL] [Abstract][Full Text] [Related]
12. Identification of Novel Selective Lysine-Specific Demethylase 1 (LSD1) Inhibitors Using a Pharmacophore-Based Virtual Screening Combined with Docking. Zhou C; Kang D; Xu Y; Zhang L; Zha X Chem Biol Drug Des; 2015 Jun; 85(6):659-71. PubMed ID: 25346381 [TBL] [Abstract][Full Text] [Related]
13. Inhibitors of enzymes catalyzing modifications to histone lysine residues: structure, function and activity. Lillico R; Stesco N; Khorshid Amhad T; Cortes C; Namaka MP; Lakowski TM Future Med Chem; 2016 May; 8(8):879-97. PubMed ID: 27173004 [TBL] [Abstract][Full Text] [Related]
14. Stable H3 peptide was delivered by gold nanorods to inhibit LSD1 activation and induce human mesenchymal stem cells differentiation. Meng X; Li J; Zheng M; Zuo L; Sun C; Zhu Y; Fang L; Liu L; Zhou X Oncotarget; 2017 Apr; 8(14):23110-23119. PubMed ID: 28416745 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents. Ma LY; Zheng YC; Wang SQ; Wang B; Wang ZR; Pang LP; Zhang M; Wang JW; Ding L; Li J; Wang C; Hu B; Liu Y; Zhang XD; Wang JJ; Wang ZJ; Zhao W; Liu HM J Med Chem; 2015 Feb; 58(4):1705-16. PubMed ID: 25610955 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of phenylcyclopropylamine compounds by enzymatic assay of lysine-specific demethylase 2 in the presence of NPAC peptide. Kakizawa T; Mizukami T; Itoh Y; Hasegawa M; Sasaki R; Suzuki T Bioorg Med Chem Lett; 2016 Feb; 26(4):1193-5. PubMed ID: 26794039 [TBL] [Abstract][Full Text] [Related]
17. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors. Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059 [TBL] [Abstract][Full Text] [Related]
18. Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine. Yang M; Culhane JC; Szewczuk LM; Jalili P; Ball HL; Machius M; Cole PA; Yu H Biochemistry; 2007 Jul; 46(27):8058-65. PubMed ID: 17569509 [TBL] [Abstract][Full Text] [Related]
19. Identification of cell-active lysine specific demethylase 1-selective inhibitors. Ueda R; Suzuki T; Mino K; Tsumoto H; Nakagawa H; Hasegawa M; Sasaki R; Mizukami T; Miyata N J Am Chem Soc; 2009 Dec; 131(48):17536-7. PubMed ID: 19950987 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of novel (E)-N'-(2,3-dihydro-1H-inden-1-ylidene) benzohydrazides as potent LSD1 inhibitors. Zhou Y; Li Y; Wang WJ; Xiang P; Luo XM; Yang L; Yang SY; Zhao YL Bioorg Med Chem Lett; 2016 Sep; 26(18):4552-4557. PubMed ID: 27524309 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]